Maija Itälä-Remes

Immunomonitoring of patients treated with mesenchymal stromal cells for steroid-refractory severe graft-versus-host disease (2017)

Cytotherapy

Keto J, Kaartinen T, Salmenniemi U, Partanen J, Hanninen A, Lahteenmaki K, Korhonen M, Itala-Remes M, Nystedt J

(Muu (O2))

Good responses but high TRM in adult patients after MSC therapy for GvHD (2017)

Bone Marrow Transplantation

Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, Korhonen M

(Kirjoitus tai data-artikkeli tieteellisessä aikakauslehdessä (B1))

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia (2017)

Leukemia and Lymphoma

Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van t' Veer MB, Tjonnfjord GE, Itala-Remesg MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, Van Oers MHJ, Geisler CH, Niemann CU

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (2017)

Journal of Clinical Oncology

Martinez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itala-Remes M, Bermudez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

A Prospective Randomized Trial Comparing Cyclosporine/Methotrexate And Tacrolimus/Sirolimus As Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation (2016)

Haematologica

Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML (2016)

Frontiers in Immunology

Impola U, Larjo A, Salmenniemi U, Putkonen M, Itala-Remes M, Partanen J

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Immunomonitoring of patients treated with mesenchymal stromal cells for graft versus host disease: a case study (2016)

Scandinavian Journal of Immunology

Keto J, Kaartinen T, Salmenniemi U, Partanen J, Hanninen A, Lahteenmaki K, Korhonen M, Itala-Remes M, Nystedt J

(Muu (O2))

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL (2014)

Blood

Geisler CH, vant' Veer MB, Jurlander J, Walewski J, Tjonnfjord G, Remes MI, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MCJ, Doorduijn J, Alemayehu WG, van Oers MHJ

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Ota yhteyttä

Linkit

Asiantuntijuusalueet

Julkaisut

Järjestä:

Immunomonitoring of patients treated with mesenchymal stromal cells for steroid-refractory severe graft-versus-host disease (2017)

Good responses but high TRM in adult patients after MSC therapy for GvHD (2017)

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia (2017)

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (2017)

A Prospective Randomized Trial Comparing Cyclosporine/Methotrexate And Tacrolimus/Sirolimus As Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation (2016)

Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML (2016)

Immunomonitoring of patients treated with mesenchymal stromal cells for graft versus host disease: a case study (2016)

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL (2014)